SLC transporters as therapeutic targets: emerging opportunities.
SLC transporters as therapeutic targets: emerging opportunities.
复制标题
DOI：
10.1038/nrd4626
复制
发表时间：
2015-08
期刊：
影响因子：
--
通讯作者：
Giacomini KM
中科院分区：
文献类型：
--
作者：
Lin L;Yee SW;Kim RB;Giacomini KM
溶质载体（SLC）转运蛋白是一个由300多种膜结合蛋白组成的家族，它们促进多种底物在生物膜上的运输，在从细胞摄取营养物质到药物和其他外源药物的吸收等生理过程中发挥着重要作用。市面上有几类药物针对众所周知的SLC转运蛋白，如神经递质转运蛋白，而人类遗传学研究已经为新近表征的SLC转运蛋白在罕见和常见疾病中的作用提供了强有力的见解，这表明了丰富的新治疗机会。本综述总结了SLC转运蛋白在人类疾病中的作用，描述了靶向这些转运蛋白的策略，并重点介绍了当前和正在研究的调节SLC转运蛋白的药物，以及有希望的药物靶点。
Solute carrier (SLC) transporters — a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes — have important roles in physiological processes ranging from the cellular uptake of nutrients to the absorption of drugs and other xenobiotics. Several classes of marketed drugs target well-known SLC transporters, such as neurotransmitter transporters, and human genetic studies have provided powerful insight into the roles of more-recently characterized SLC transporters in both rare and common diseases, indicating a wealth of new therapeutic opportunities. This Review summarizes knowledge on the roles of SLC transporters in human disease, describes strategies to target such transporters, and highlights current and investigational drugs that modulate SLC transporters, as well as promising drug targets.